darzalex faspro
(daratumumab and hyaluronidase-fihj (human recombinant))Janssen Biotech, Inc.
Usage: DARZALEX FASPRO is indicated for treating adult patients with multiple myeloma, either in combination with other therapies or as monotherapy after multiple prior treatments. It is also approved for newly diagnosed light chain amyloidosis in combination with specific medications, with ongoing approval contingent on further clinical trials.